Mural Oncology Announces Scheme of Arrangement Effective
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 05 2025
0mins
Should l Buy XOMA?
Mural Oncology (MURA) announces that the scheme of arrangement between Mural and its shareholders under Chapter 1 of Part 9 of the Companies Act 2014 pursuant to which XRA 5 Corp., a wholly-owned subsidiary of XOMA Royalty Corporation (XOMA) will acquire the entire issued and to be issued share capital of Mural, became effective today, 5 December 2025. Distribution of cheques and crediting of DTC participant accounts for the cash consideration paid by Sub to Scheme Shareholders under the terms of the Scheme is expected to commence as soon as practicable following the Effective Date, with DTC participant accounts expected to be credited and the distribution of cheques expected to be complete as soon as practicable. In accordance with the requirements of the Irish Takeover Rules, all consideration paid by Sub to Scheme Shareholders under the terms of the Scheme will be distributed by no later than 19 December 2025.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy XOMA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on XOMA
Wall Street analysts forecast XOMA stock price to rise
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 41.890
Low
50.00
Averages
71.00
High
97.00
Current: 41.890
Low
50.00
Averages
71.00
High
97.00
About XOMA
XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Background: Halper Sadeh LLC is investigating companies like Select Medical Holdings, XOMA Royalty Corporation, Soleno Therapeutics, and KORE Group Holdings for potential violations of federal securities laws and fiduciary duties, which may impact shareholder rights.
- Select Medical Transaction: Shareholders of Select Medical may face a sale to a consortium led by executives at $16.50 per share, with Halper Sadeh LLC potentially seeking increased consideration and additional disclosures to protect shareholder interests.
- XOMA Royalty Transaction: XOMA Royalty Corporation shareholders are set to sell to Ligand Pharmaceuticals for $39.00 per share, and Halper Sadeh LLC may advocate for higher transaction prices and transparency to ensure shareholders' legal rights are upheld.
- Soleno and KORE Transactions: Soleno Therapeutics shareholders will sell to Neurocrine Biosciences for $53.00 per share, while KORE Group Holdings shareholders will sell to Searchlight Capital Partners and Abry Partners for $9.25 per share, with Halper Sadeh LLC providing legal support to ensure these shareholders' rights are protected.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Merger Investigation: Halper Sadeh LLC is investigating the merger between Helix Energy Solutions Group, Inc. and Hornbeck Offshore Services, Inc., with Helix shareholders expected to own approximately 45% of the combined entity, potentially impacting shareholder rights and future earnings.
- Acquisition Review: Organon & Co. is being sold to Sun Pharmaceutical Industries Limited for $14.00 per share, and Halper Sadeh LLC may seek increased compensation and additional disclosures to ensure shareholder rights are protected.
- Equity Transaction: XOMA Royalty Corporation is being sold to Ligand Pharmaceuticals Incorporated for $39.00 per share, with Halper Sadeh LLC representing shareholders to investigate the compliance of this transaction and ensure fair terms for shareholders.
- RE/MAX Deal: RE/MAX Holdings, Inc. is in a transaction with The Real Brokerage Inc., allowing shareholders to choose either 5.152 shares or $13.80 in cash per share, with Halper Sadeh LLC providing legal support to safeguard shareholder interests.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Background: Halper Sadeh LLC is investigating companies such as XOMA Royalty Corporation, RE/MAX Holdings, Inc., and Galera Therapeutics, Inc. for potential violations of federal securities laws and breaches of fiduciary duties, which may impact shareholders' financial interests.
- XOMA Transaction Details: XOMA Royalty Corporation is being sold to Ligand Pharmaceuticals Incorporated for $39.00 per share, a transaction that may limit the emergence of superior competing offers, thereby affecting shareholders' options.
- RE/MAX Shareholder Choices: Shareholders of RE/MAX Holdings, Inc. can choose to sell their shares for either 5.152 shares of the combined company or $13.80 in cash per share, with Halper Sadeh LLC encouraging shareholders to understand their rights and options to ensure fair treatment.
- Galera Merger Impact: The merger between Galera Therapeutics, Inc. and Obsidian Therapeutics, Inc. is expected to result in Galera shareholders owning approximately 1.8% of the combined company, with Halper Sadeh LLC potentially seeking increased compensation and additional disclosures to protect shareholder interests.
See More
Investigation Alerts for Multiple Company Mergers
- XOMA Acquisition Deal: XOMA Royalty Corporation is set to be acquired by Ligand Pharmaceuticals for $39.00 per share, totaling approximately $739 million; however, this price is below its 52-week high of $42.38, raising concerns among shareholders about the fairness of the transaction.
- Organon Merger Case: Organon & Co. will be acquired by Sun Pharmaceutical for $14.00 per share, with an enterprise valuation of $11.75 billion, and the investigation focuses on whether the Organon Board failed to uphold fiduciary duties to ensure a fair process for shareholders.
- RE/MAX Merger Investigation: RE/MAX Holdings, Inc. is being acquired by The Real Brokerage Inc., allowing shareholders to choose between 5.152 shares of the new company or $13.80 in cash, with investigations looking into whether the Board adequately handled the transaction to protect shareholder interests.
- Soleno Acquisition Case: Soleno Therapeutics, Inc. will be acquired by Neurocrine Biosciences for $53.00 per share, representing a total equity value of approximately $2.9 billion, while the investigation questions whether the Board ensured the deal was fair to shareholders, given that the price is below its 52-week high of $90.32.
See More
Class Action Developments for Multiple Companies' Shareholders
- XOMA Shareholder Payout: XOMA Royalty Corporation is set to be sold to Ligand Pharmaceuticals for $39.00 per share in cash, which is expected to provide substantial returns for shareholders and enhance its market appeal.
- RE/MAX Shareholder Options: Shareholders of RE/MAX Holdings, Inc. will have the choice of receiving either 5.152 shares of the combined company or $13.80 in cash per share, which will strengthen its competitive position in the real estate market.
- Galera Merger Shares: Following the merger with Obsidian Therapeutics, Inc., Galera Therapeutics, Inc. shareholders will own approximately 1.8% of the combined company, indicating its potential for integration in the biotechnology sector.
- Avanos Cash Return: Avanos Medical, Inc. is being sold to affiliates of American Industrial Partners for $25.00 per share in cash, which is expected to provide direct cash returns to shareholders and enhance its financial stability.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Focus: Halper Sadeh LLC is investigating companies such as XOMA Royalty Corporation, RE/MAX Holdings, Inc., and KalVista Pharmaceuticals, Inc. for potential violations of federal securities laws and breaches of fiduciary duties, which may impact shareholder rights.
- Transaction Details: XOMA is being sold to Ligand Pharmaceuticals for $39.00 per share, RE/MAX is selling for either 5.152 shares or $13.80 in cash per share to The Real Brokerage, and KalVista is being sold for $27.00 per share in cash to Chiesi Group, with terms that may limit superior competing offers.
- Shareholder Rights Protection: Halper Sadeh LLC encourages shareholders to contact them to discuss their rights and options at no cost, indicating the firm’s commitment to providing risk-free legal support for investors.
- Legal Service Commitment: The firm represents investors globally, focusing on combating securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for defrauded investors, showcasing its expertise and effectiveness in protecting shareholder interests.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Background: Halper Sadeh LLC is investigating companies like Select Medical Holdings, XOMA Royalty Corporation, Soleno Therapeutics, and KORE Group Holdings for potential violations of federal securities laws and fiduciary duties, which may impact shareholder rights.
- Select Medical Transaction: Shareholders of Select Medical may face a sale to a consortium led by executives at $16.50 per share, with Halper Sadeh LLC potentially seeking increased consideration and additional disclosures to protect shareholder interests.
- XOMA Royalty Transaction: XOMA Royalty Corporation shareholders are set to sell to Ligand Pharmaceuticals for $39.00 per share, and Halper Sadeh LLC may advocate for higher transaction prices and transparency to ensure shareholders' legal rights are upheld.
- Soleno and KORE Transactions: Soleno Therapeutics shareholders will sell to Neurocrine Biosciences for $53.00 per share, while KORE Group Holdings shareholders will sell to Searchlight Capital Partners and Abry Partners for $9.25 per share, with Halper Sadeh LLC providing legal support to ensure these shareholders' rights are protected.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Merger Investigation: Halper Sadeh LLC is investigating the merger between Helix Energy Solutions Group, Inc. and Hornbeck Offshore Services, Inc., with Helix shareholders expected to own approximately 45% of the combined entity, potentially impacting shareholder rights and future earnings.
- Acquisition Review: Organon & Co. is being sold to Sun Pharmaceutical Industries Limited for $14.00 per share, and Halper Sadeh LLC may seek increased compensation and additional disclosures to ensure shareholder rights are protected.
- Equity Transaction: XOMA Royalty Corporation is being sold to Ligand Pharmaceuticals Incorporated for $39.00 per share, with Halper Sadeh LLC representing shareholders to investigate the compliance of this transaction and ensure fair terms for shareholders.
- RE/MAX Deal: RE/MAX Holdings, Inc. is in a transaction with The Real Brokerage Inc., allowing shareholders to choose either 5.152 shares or $13.80 in cash per share, with Halper Sadeh LLC providing legal support to safeguard shareholder interests.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Background: Halper Sadeh LLC is investigating companies such as XOMA Royalty Corporation, RE/MAX Holdings, Inc., and Galera Therapeutics, Inc. for potential violations of federal securities laws and breaches of fiduciary duties, which may impact shareholders' financial interests.
- XOMA Transaction Details: XOMA Royalty Corporation is being sold to Ligand Pharmaceuticals Incorporated for $39.00 per share, a transaction that may limit the emergence of superior competing offers, thereby affecting shareholders' options.
- RE/MAX Shareholder Choices: Shareholders of RE/MAX Holdings, Inc. can choose to sell their shares for either 5.152 shares of the combined company or $13.80 in cash per share, with Halper Sadeh LLC encouraging shareholders to understand their rights and options to ensure fair treatment.
- Galera Merger Impact: The merger between Galera Therapeutics, Inc. and Obsidian Therapeutics, Inc. is expected to result in Galera shareholders owning approximately 1.8% of the combined company, with Halper Sadeh LLC potentially seeking increased compensation and additional disclosures to protect shareholder interests.
See More
Investigation Alerts for Multiple Company Mergers
- XOMA Acquisition Deal: XOMA Royalty Corporation is set to be acquired by Ligand Pharmaceuticals for $39.00 per share, totaling approximately $739 million; however, this price is below its 52-week high of $42.38, raising concerns among shareholders about the fairness of the transaction.
- Organon Merger Case: Organon & Co. will be acquired by Sun Pharmaceutical for $14.00 per share, with an enterprise valuation of $11.75 billion, and the investigation focuses on whether the Organon Board failed to uphold fiduciary duties to ensure a fair process for shareholders.
- RE/MAX Merger Investigation: RE/MAX Holdings, Inc. is being acquired by The Real Brokerage Inc., allowing shareholders to choose between 5.152 shares of the new company or $13.80 in cash, with investigations looking into whether the Board adequately handled the transaction to protect shareholder interests.
- Soleno Acquisition Case: Soleno Therapeutics, Inc. will be acquired by Neurocrine Biosciences for $53.00 per share, representing a total equity value of approximately $2.9 billion, while the investigation questions whether the Board ensured the deal was fair to shareholders, given that the price is below its 52-week high of $90.32.
See More
Class Action Developments for Multiple Companies' Shareholders
- XOMA Shareholder Payout: XOMA Royalty Corporation is set to be sold to Ligand Pharmaceuticals for $39.00 per share in cash, which is expected to provide substantial returns for shareholders and enhance its market appeal.
- RE/MAX Shareholder Options: Shareholders of RE/MAX Holdings, Inc. will have the choice of receiving either 5.152 shares of the combined company or $13.80 in cash per share, which will strengthen its competitive position in the real estate market.
- Galera Merger Shares: Following the merger with Obsidian Therapeutics, Inc., Galera Therapeutics, Inc. shareholders will own approximately 1.8% of the combined company, indicating its potential for integration in the biotechnology sector.
- Avanos Cash Return: Avanos Medical, Inc. is being sold to affiliates of American Industrial Partners for $25.00 per share in cash, which is expected to provide direct cash returns to shareholders and enhance its financial stability.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Focus: Halper Sadeh LLC is investigating companies such as XOMA Royalty Corporation, RE/MAX Holdings, Inc., and KalVista Pharmaceuticals, Inc. for potential violations of federal securities laws and breaches of fiduciary duties, which may impact shareholder rights.
- Transaction Details: XOMA is being sold to Ligand Pharmaceuticals for $39.00 per share, RE/MAX is selling for either 5.152 shares or $13.80 in cash per share to The Real Brokerage, and KalVista is being sold for $27.00 per share in cash to Chiesi Group, with terms that may limit superior competing offers.
- Shareholder Rights Protection: Halper Sadeh LLC encourages shareholders to contact them to discuss their rights and options at no cost, indicating the firm’s commitment to providing risk-free legal support for investors.
- Legal Service Commitment: The firm represents investors globally, focusing on combating securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for defrauded investors, showcasing its expertise and effectiveness in protecting shareholder interests.
See More
